Pennington Stephanie, Stutzman Danielle, Sannar Elise
J Pediatr Pharmacol Ther. 2021;26(4):405-410. doi: 10.5863/1551-6776-26.4.405. Epub 2021 May 19.
This case report evaluates the potential benefit of pitolisant in a 15-year-old female with Prader-Willi syndrome, obsessive-compulsive disorder, autism spectrum disorder, and mild intellectual disability. Due to its action on the H3 receptor, it enhances central activity of histaminergic neurons resulting in increased alertness, irrespective of the loss of orexin neurons seen in narcolepsy. Additionally, it is thought to modulate various other neurotransmitter systems including acetylcholine, norepinephrine, and dopamine. Pitolisant has the potential to improve many symptoms in patients with Prader-Willi syndrome and it appears to be well tolerated with minimal side effects observed. Therefore, the use of pitolisant should be considered in patients with Prader-Willi syndrome who fail a psychostimulant trial.
本病例报告评估了匹莫林对一名患有普拉德-威利综合征、强迫症、自闭症谱系障碍和轻度智力障碍的15岁女性的潜在益处。由于其对H3受体的作用，它增强了组胺能神经元的中枢活性，从而提高警觉性，无论发作性睡病中所见的食欲素神经元缺失情况如何。此外，它还被认为可调节包括乙酰胆碱、去甲肾上腺素和多巴胺在内的各种其他神经递质系统。匹莫林有可能改善普拉德-威利综合征患者的许多症状，并且似乎耐受性良好，观察到的副作用最小。因此，对于精神兴奋剂试验失败的普拉德-威利综合征患者，应考虑使用匹莫林。
